Assessment of the Risk of Hepatotoxicity with Kava ProductsThere has been international concern over the association of kava products and serious hepatotoxicity. Regulatory action banning these products in Europe has been controversial. The objective of this report is to investigate the possibility of hepatotoxicity with kava. It contains a description of kava and provides safety information as well as information on regulatory issues, conclusions and recommendations by the Committee appointed to handle this enquiry. |
Common terms and phrases
acetonic acetonic and ethanolic Acetonic extract Adverse effects adverse events alcohol anxiety disorders anxiolytics assessment associated with kava ATC code benzodiazepines BfArM causality Cholestatic hepatitis Clinical Trial Control database Denham Diclofenac dihydromethysticin dose double-blind Drug effects of kava EMEA Ernst Ethanol ethanolic extracts evaluation extract WS 1490 extracts of kava Fiji German Gruenwald Health hepatic events Hepatic failure Hepatic failure Yes Hepatic function Hepatic necrosis Hepatitis cholestatic hepatotoxicity hepatotoxicity with kava herbal medicines interactions kava lactones kava Piper methysticum kava preparations kava products kava pyrones kava root kava-containing products kava-drug Kavain Laitan Lebot liver damage liver disease liver injury liver toxicity liver transplants Medical Journal Necrotising hepatitis Number of subjects organic extracts patients Pharmacology pharmacovigilance Phytomedicine Phytopharm Phytotherapy Piper methysticum placebo plant Planta Medica potential Psychopharmacology pyrones rechallenge Recovered regulatory reports of hepatotoxicity Review risk Schmidt Singh YN Stickel Suva synthetic products Table treatment water extracts
Popular passages
Page 26 - J (1996) Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A doubleblind placebo-controlled study of four weeks treatment.
Page 28 - Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders- a randomized placebo-controlled 25-week outpatient trial.
Page 2 - Library contains the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effectiveness, and The Cochrane Controlled Trials Register.
Page 25 - Kavakava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients.
Page 73 - Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain.
Page 3 - Database) is a bibliographic database produced by the Health Care Information Service of the British Library. It covers a selection of journals in three separate subject areas: several professions allied to medicine, complementary medicine and palliative care.
Page 65 - Anticonvulsive action of (+/— )-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites.
Page 80 - C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol 1992;215:265-9.
Page 74 - Walden J, von Wegerer J, Winter U, Berger M, Grunze H. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Progress Neuropsychopharmacol Biol Psychiat 1997:21:697-706.
Page 26 - Efficacy and safety of herbal stimulants and sedatives in sleep disorders', Sleep Medicine Reviews, vol.